Orchard Therapeutics, recognized for its pioneering work in hematopoietic stem cell gene therapies, operates within the competitive biotechnology and rare disease therapeutics sector. Its primary peer group and industry competitors include other specialized gene and cell therapy developers such as Bluebird Bio, Editas Medicine, CRISPR Therapeutics, Beam Therapeutics, and Autolus Therapeutics, all striving to advance transformative genetic medicines for severe inherited conditions.